A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Exclusion Criteria

• •1. Prior treatment anti-cancer therapy or use of any investigational agent within the past 28 days or 5 half-lives, whichever is shorter;
• •2. Toxicity from prior chemotherapy that has not resolved to Grade ≤ 1;
• •3. Radiotherapy within the last 21 days;
• •4. Primary brain tumors or CNS metastases;
• •5. Major or minor surgery \< 28 and \<14 days from the start of treatment, respectively;
• •6. Active autoimmune disease or any medical condition requiring the use of systemic immunosuppressive medications;
• •7. Endocrinopathies, unless on stable hormone replacement therapy;
• •8. Active infection requiring systemic therapy;
• •9. Receipt of live vaccines against infectious diseases within 28 days;
• •10. HIV positive or an AIDS-related illness;
• •11. Active/chronic HBV or HCV infection;
• •12. Uncontrolled CHF (NYHA Class 2-4), angina, MI, CVA, coronary/peripheral artery bypass graft surgery, TIA, or PE in prior 3 months;
• •13. Cardiac dysrhythmias;
• •14. Gastrointestinal disease that interferes with receipt of oral drugs;
• •15. Concomitant malignancy;
• •16. Pregnant or lactating female;